Full-Time

Quality Control Analyst

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

No salary listed

Mid

No H1B Sponsorship

Dublin, Ireland

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Requirements
  • A minimum of a BSc. in science or a related discipline, providing a strong foundation in scientific principles and methodologies
  • Proven experience in the pharmaceutical industry, showcasing your ability to navigate and excel in a highly regulated environment.
  • At least 2-3 years of hands-on experience in an analytical lab, demonstrating your proficiency in laboratory techniques and procedures.
  • Excellent organizational, communication, interpersonal, and report writing skills, enabling you to effectively manage tasks and collaborate with team members.
  • Adaptability to changing priorities, ensuring you can thrive in a dynamic and fast-paced work environment.
Responsibilities
  • Ensure strict adherence to GLP/cGMP standards.
  • Conduct comprehensive testing of laboratory samples.
  • Perform laboratory tests following written procedures or pharmacopoeia guidelines.
  • Accurately record and report analytical results.
  • Operate, maintain, and calibrate laboratory instruments.
  • Develop and execute validation protocols for instruments and methods.
  • Maintain detailed and up-to-date training records.
  • Keep the laboratory environment clean, organized, and safe.
  • Manage the ordering, receiving, and control of laboratory chemicals, reagents, and consumables.
  • Promote and embody the corporate values of Takeda-ism and foster a culture of safety awareness.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.